Croma-Pharma
Alexandra Baer-Zwick has extensive experience in regulatory affairs and pharmacovigilance. Alexandra is currently serving as the Head of Regulatory Affairs-GCD and Deputy QPPV at CROMA-PHARMA since 2020. In this role, they are responsible for international registrations of medical devices and the development of the pharmacovigilance system of the company.
Prior to their current position, they worked as a Senior Manager Regulatory Affairs and Deputy QPPV at CROMA-PHARMA from 2009 to 2020. Alexandra also has experience as an Assistance Program Manager for EU FP7 Health Programme at FFG Österreichische Forschungsförderungsgesellschaft mbH and as a Post Doc at Medical University of Vienna.
Alexandra Baer-Zwick holds a PhD from the University of Vienna and has previous experience in psychologische diagnostik at St. Anna Kinderspital.
Alexandra Baer-Zwick earned a Master's degree in Genetics/Microbiology from Universität Wien in 1999-2004. Alexandra then pursued further education at the University of Vienna, where they obtained a second Master's degree in Psychology from 1997-2005. Finally, they completed a Doctor of Philosophy (PhD) in Genetics/Microbiology at the University of Vienna from 2005-2008.
This person is not in any offices
Croma-Pharma
4 followers
Croma is a global player in the minimally invasive aesthetics market and a leading European manufacturer of premium quality hyaluronic acid syringes. The company offers a comprehensive and innovative aesthetics portfolio including botulinum toxin, fillers, lifting threads and biostimulators complemented by its own skincare brand. Founded in 1976 by a pharmacist couple, Croma-Pharma GmbH is a family company headquartered in Austria where it also operates its manufacturing plant. With 550 employees, 13 subsidiaries in Europe and Brazil, two joint ventures and 60 exclusive export partners, it distributes its products in 80 markets globally, including the US, Canada, China, Australia and New Zealand. It also operates as a contract manufacturer in orthopaedics and ophthalmology. For more information please visit cromapharma.com.